On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Lymphoma Hub Steering Committee member Francesc Bosch, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES, led a case-based presentation and panel discussion featuring Susan O’Brien, Farrukh Awan, and Gilles Salles on optimizing chronic lymphocytic leukemia management in a changing landscape.

This educational activity is independently supported by Eli Lilly and Company. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.

On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Farrukh Awan, University of Texas Southwestern Medical Center, Dallas, US, delivered a presentation on BTK inhibitors in practice: Treatment selection and emerging clinical evidence.

This educational resource is independently supported by Eli Lilly and Company. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.

On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Lymphoma Hub Steering Committee member Susan O’Brien, University of California Irvine, US, delivered a presentation on BTK inhibitors in chronic lymphocytic leukemia: Mechanisms, clinical considerations, and unmet needs.

This educational resource is independently supported by Eli Lilly and Company. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.